Ampullary cancer is a rare malignancy that develops in a small but crucial junction where the digestive system’s drainage channels meet, making early detection and specialized treatment essential for managing this challenging condition.

Understanding Treatment Goals and Available Options

When someone receives a diagnosis of ampullary cancer, understanding the treatment landscape becomes crucial for making informed decisions. The main goal of treating this rare cancer is to remove the tumor completely whenever possible, which offers the best chance of long-term survival. However, treatment approaches must be tailored to each person’s unique situation, considering factors like the tumor’s size, how far it has spread, the patient’s overall health, and their ability to tolerate complex procedures.^[1]

Medical teams recognize that ampullary cancer sits in a particularly challenging location where the bile duct from the liver and the pancreatic duct join together before emptying into the small intestine. This anatomical complexity means that treatment decisions require careful consideration by specialists experienced in managing cancers of the digestive system. The ampulla of Vater, where this cancer originates, is so close to vital organs like the liver, pancreas, and intestines that treating the cancer often affects these neighboring structures.^[2]

Standard treatments approved by medical societies have been established based on decades of surgical experience, while researchers continue investigating new approaches through clinical trials. For patients whose cancer is caught early and hasn’t spread beyond the ampulla, surgery offers the possibility of removing the disease entirely. For those with more advanced cancer or who cannot undergo major surgery, other treatment options focus on controlling symptoms, maintaining quality of life, and potentially slowing the cancer’s progression.^[9]

The treatment journey typically involves multiple specialists working together, including surgeons, medical oncologists who manage chemotherapy, radiation oncologists, and diagnostic specialists. This team approach ensures that every aspect of care is coordinated, from initial diagnosis through surgery, recovery, and any additional treatments that may be needed afterward. Treatment recommendations are typically discussed in specialized tumor boards, where multiple experts review each case to determine the most appropriate strategy.^[10]

Standard Surgical Treatment

Surgery remains the cornerstone of treatment for ampullary cancer when the tumor can be completely removed. The primary surgical procedure is called pancreaticoduodenectomy, commonly known as the Whipple procedure. This complex operation involves removing the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder, and part of the bile duct. The surgeon then reconstructs the digestive system by connecting the remaining organs to allow food and digestive juices to flow properly.^[9]

A variation of this surgery is called pylorus-preserving pancreaticoduodenectomy, where surgeons leave the stomach outlet intact. This modification can sometimes lead to better nutritional outcomes after surgery because it preserves normal stomach function. The choice between these two approaches depends on the tumor’s exact location and the surgeon’s assessment of what will achieve complete cancer removal while maintaining the best possible digestive function.^[22]

The surgery itself typically lasts several hours and requires a hospital stay of one to two weeks, though recovery continues for several months afterward. Because of the procedure’s complexity, it’s ideally performed at specialized centers where surgical teams have extensive experience with these operations. Studies have shown that patients treated at high-volume centers, where surgeons regularly perform these procedures, tend to have better outcomes and fewer complications.^[5]

For very small tumors that haven’t spread into surrounding tissues, some patients may be candidates for a less extensive procedure called local excision or ampullectomy. This approach removes only the tumor and immediate surrounding tissue without taking out the entire pancreas head. However, this option is suitable only for highly selected patients with very early-stage disease, as there is a higher risk of cancer recurrence compared to the more extensive Whipple procedure.^[7]

During surgery, surgeons also perform systematic lymphadenectomy, which means removing lymph nodes in the region to check for cancer spread. The presence or absence of cancer in these lymph nodes is one of the most important factors in predicting long-term outcomes. Patients without lymph node involvement generally have much better survival rates than those whose cancer has spread to nearby lymph nodes.^[5]

Survival rates after surgical removal vary considerably based on the cancer’s stage and characteristics. For localized disease that hasn’t spread to lymph nodes or invaded deeply into the pancreas, five-year survival rates can range from 40% to 75%. When the cancer has spread to lymph nodes or invaded the pancreas more extensively, five-year survival drops to 10% to 40%. These numbers are significantly better than for pancreatic cancer itself, which is one reason why accurate diagnosis of ampullary cancer is so important.^[5]

Several factors influence long-term outcomes after surgery. Pathologists examine the removed tissue carefully to determine whether the surgical margins are clear, meaning no cancer cells are visible at the edges of the removed tissue. Clear margins, absence of lymph node spread, smaller tumor size, well-differentiated cancer cells (meaning they look more like normal cells), and lack of invasion into the pancreas are all associated with better outcomes. The tumor’s histological subtype also matters—there are two main types called intestinal and pancreaticobiliary, with the intestinal type generally having a better prognosis.^[10]

Additional Treatments After Surgery

After surgical removal of ampullary cancer, doctors may recommend additional treatments to reduce the risk of cancer returning. These treatments, called adjuvant therapy, are designed to eliminate any cancer cells that might remain in the body even though they can’t be detected. The decision to use adjuvant therapy depends on several factors found during pathology examination of the removed tumor, including whether cancer had spread to lymph nodes, how deeply it invaded surrounding tissues, and whether the surgical margins were completely clear.^[11]

The role of adjuvant chemotherapy and radiation therapy in ampullary cancer remains somewhat controversial because this cancer is so rare that large, definitive studies have been difficult to conduct. Unlike some cancers where clear guidelines exist, treatment decisions after ampullary cancer surgery often draw from evidence about related cancers of the bile duct, pancreas, and colon. Many medical centers base their recommendations on each patient’s individual risk factors rather than following a one-size-fits-all approach.^[10]

Chemotherapy uses drugs to kill cancer cells throughout the body. One commonly used drug is 5-fluorouracil (often called 5-FU), which interferes with cancer cell division and has been studied in patients with ampullary cancer. Another drug called capecitabine works similarly but can be taken by mouth rather than through intravenous infusion, making it more convenient for patients. Some treatment centers combine chemotherapy drugs—for example, using capecitabine together with oxaliplatin in a regimen called CAPOX. A Phase II clinical trial testing CAPOX in patients with advanced ampullary cancer reported improved survival compared to historical results with other treatments.^[11]

Radiation therapy uses high-energy beams to kill cancer cells in a specific area. When used after ampullary cancer surgery, radiation is aimed at the surgical area to eliminate any microscopic cancer cells that might remain. Radiation is often combined with chemotherapy (called chemoradiation) because the chemotherapy drugs can make cancer cells more sensitive to radiation damage. Typical radiation doses range from 40 to 50 gray (Gy) delivered over several weeks. Some studies have suggested that adjuvant chemoradiation may improve local control of the cancer, meaning it’s less likely to grow back in the same area, particularly in patients whose cancer had spread to lymph nodes.^[11]

Research from major cancer centers has provided some guidance, though results have been mixed. The Mayo Clinic reported that patients with lymph node-positive disease who received adjuvant radiation therapy (median dose 50.4 Gy) combined with 5-fluorouracil had better overall survival compared to surgery alone (3.4 years versus 1.6 years). However, this benefit was less clear for patients with locally advanced tumors without lymph node spread. Other institutions have reported similar trends suggesting potential benefits for high-risk patients, though these studies have been limited by small patient numbers.^[11]

Side effects from adjuvant chemotherapy can include nausea, vomiting, diarrhea, fatigue, increased infection risk due to low white blood cell counts, and numbness or tingling in the hands and feet (called peripheral neuropathy) particularly with oxaliplatin. Radiation therapy side effects may include fatigue, skin irritation in the treatment area, nausea, and diarrhea. These side effects are typically temporary and resolve after treatment ends, though some patients may experience longer-lasting effects. Medical teams work closely with patients to manage these side effects and maintain quality of life during treatment.^[11]

Treatment for Advanced or Metastatic Cancer

When ampullary cancer has spread to distant organs or cannot be removed surgically due to involvement of major blood vessels or other structures, the treatment focus shifts from attempting cure to controlling the cancer and maintaining quality of life. This is called palliative treatment. While the term “palliative” might sound discouraging, these treatments can still significantly extend survival and help patients feel better by relieving symptoms caused by the cancer.^[11]

For patients whose cancer is blocking the bile duct and causing jaundice, one important palliative procedure is endoscopic stent placement. A gastroenterologist uses an endoscope (a flexible tube with a camera) to reach the blocked bile duct and insert a small tube called a stent. This stent holds the duct open, allowing bile to drain properly and relieving the yellow discoloration, itching, and other problems caused by bile backup. This procedure can dramatically improve a patient’s comfort and quality of life without requiring major surgery.^[11]

Chemotherapy for advanced ampullary cancer often draws from treatment strategies used for related cancers. Because ampullary cancer can arise from different types of tissue and behave somewhat like colon cancer, bile duct cancer, or pancreatic cancer depending on its specific characteristics, oncologists may tailor chemotherapy based on the tumor’s histological subtype. For tumors with intestinal features, treatment approaches similar to those used for colorectal cancer may be considered. For tumors with pancreaticobiliary features, strategies used for pancreatic or bile duct cancers might be more appropriate.^[11]

Gemcitabine is a chemotherapy drug that has shown promise in treating biliary tract cancers, and this experience has been extended to ampullary cancer patients with pancreaticobiliary features. Gemcitabine can be used alone or combined with other drugs. The CAPOX regimen (capecitabine plus oxaliplatin) mentioned earlier has also been studied in the palliative setting, with a Phase II study reporting median overall survival of 20.4 months in patients with metastatic disease, compared to 15.5 months seen with other approaches in similar patient groups.^[11]

Because ampullary cancer is so rare, there isn’t enough evidence to make definitive recommendations about the single best chemotherapy approach for advanced disease. Treatment decisions are typically made through discussion in multidisciplinary tumor boards, where specialists review each patient’s specific situation including their overall health, the cancer’s characteristics, and what treatments they’ve already received. Many experts believe that considering the tumor’s histological subtype is important when choosing palliative chemotherapy.^[10]

Innovative Treatments Being Tested in Clinical Trials

Because standard treatments for ampullary cancer have limitations and many questions remain about the best approaches, researchers are actively investigating new treatment strategies through clinical trials. These studies test promising therapies that aren’t yet widely available, offering hope for improving outcomes in this rare cancer. Clinical trials proceed through phases, with Phase I focusing on safety and dosing, Phase II examining whether a treatment shows promising effectiveness, and Phase III comparing new treatments directly against current standards.^[10]

One important area of investigation involves understanding the molecular characteristics of ampullary cancer at a deeper level. Scientists are studying the specific genetic mutations and molecular changes that drive these tumors, with the hope of identifying targeted therapies that attack cancer cells based on their unique vulnerabilities. Researchers have identified that ampullary cancers can harbor various genetic alterations, and ongoing studies aim to determine whether drugs targeting these specific abnormalities might be effective.^[2]

The recognition that ampullary cancer comprises different histological subtypes—primarily intestinal and pancreaticobiliary—has opened new research directions. These subtypes have different molecular profiles and clinical behaviors, with the pancreaticobiliary type generally carrying a worse prognosis (median survival 33-41 months versus 72-80 months for the intestinal type). Current research is exploring whether developing subtype-specific treatments could improve outcomes, though targeted treatments aren’t yet available for either subtype.^[10]

Immunotherapy represents another promising research direction. These treatments work by helping the patient’s own immune system recognize and attack cancer cells. Some cancers respond dramatically to immunotherapy drugs called checkpoint inhibitors, which remove the brakes that normally prevent immune cells from attacking the body’s own tissues. Researchers are investigating whether certain ampullary cancers, particularly those with specific molecular features like microsatellite instability, might be responsive to immunotherapy approaches. Early-stage studies are evaluating these possibilities, though results specific to ampullary cancer are still emerging.^[10]

Some researchers have explored using chemotherapy and radiation therapy before surgery (called neoadjuvant therapy) rather than only afterward. The idea is that treating the cancer first might shrink it, making surgery easier and more likely to remove all the cancer. One small study reported on four patients with duodenal or ampullary cancer who received neoadjuvant chemoradiation; remarkably, when surgery was performed, no residual tumor was found in any of the four pancreaticoduodenectomy specimens. While these results are intriguing, much more research is needed to understand whether this approach could benefit larger numbers of patients.^[11]

Because ampullary cancer is rare, clinical trials often enroll patients across multiple centers nationally or internationally to gather enough participants. Patients interested in clinical trial participation should discuss this option with their medical team. Trials may be available at major cancer centers in the United States, Europe, and other regions. These studies often have specific eligibility criteria regarding the cancer’s stage, previous treatments received, and the patient’s overall health status.^[10]

Most common treatment methods

• Surgical removal
  • Whipple procedure (pancreaticoduodenectomy) removing the pancreas head, duodenum, gallbladder, and part of the bile duct
  • Pylorus-preserving pancreaticoduodenectomy, which leaves the stomach outlet intact for potentially better digestive function
  • Local excision (ampullectomy) for very small, early-stage tumors
  • Systematic lymphadenectomy to remove regional lymph nodes
• Chemotherapy
  • 5-fluorouracil (5-FU) administered intravenously, interfering with cancer cell division
  • Capecitabine, an oral drug with similar effects to 5-FU
  • CAPOX regimen combining capecitabine and oxaliplatin
  • Gemcitabine for tumors with pancreaticobiliary features
• Radiation therapy
  • External beam radiation delivering 40-50 Gy over several weeks to the surgical area
  • Chemoradiation combining radiation with chemotherapy drugs as radiosensitizers
• Endoscopic procedures
  • Stent placement to relieve bile duct obstruction and jaundice
  • Endoscopic biopsy for tissue diagnosis
• Investigational approaches in clinical trials
  • Targeted therapies based on molecular characteristics of the tumor
  • Immunotherapy with checkpoint inhibitors
  • Neoadjuvant chemoradiation administered before surgery